Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amgen ( (AMGN) ) has issued an update.
On April 22, 2026, Amgen announced that David M. Reese, M.D., executive vice president and chief technology officer, will retire effective June 30, 2026, after a tenure that included leading research and development from 2018 to 2023 and championing early adoption of artificial intelligence across the business. Reese will remain an executive vice president until his retirement date and will receive the retirement benefits available under the company’s existing plans.
To deepen the integration of science and technology and support its “convergent innovation” strategy, Amgen will redistribute the CTO responsibilities and implement a series of leadership changes effective June 1, 2026, including appointing James Bradner as executive vice president of Research and Development, Artificial Intelligence and Data, naming Sean Bruich as senior vice president and chief technology officer, expanding Murdo Gordon’s remit to executive vice president of Amgen Global Markets and Policy, and confirming Paul Burton as senior vice president and chief medical officer. These moves are intended to better align R&D, AI, data, medical and commercial functions with the growing use of advanced technologies across the healthcare ecosystem, reinforcing Amgen’s competitive positioning and operational focus on technology-driven drug discovery and patient engagement.
The most recent analyst rating on (AMGN) stock is a Hold with a $335.00 price target. To see the full list of analyst forecasts on Amgen stock, see the AMGN Stock Forecast page.
Spark’s Take on AMGN Stock
According to Spark, TipRanks’ AI Analyst, AMGN is a Outperform.
AMGN scores positively overall, led by strong technical strength and supportive earnings-call outlook with defined 2026 guidance and broad product momentum. The main constraint is financial risk from high leverage and a recent decline in free cash flow, while valuation is reasonable but not cheap given the ~23.8 P/E, partially offset by a ~2.6% dividend yield.
To see Spark’s full report on AMGN stock, click here.
More about Amgen
Amgen is a U.S.-based biotechnology company that discovers, develops, manufactures and delivers innovative medicines for cancer, inflammatory conditions, rare diseases, heart disease and obesity-related conditions. Founded more than 45 years ago and headquartered in Thousand Oaks, Calif., it leverages biology, human genetic data and advanced technology to reach millions of patients worldwide and is a member of the Dow Jones Industrial Average and the Nasdaq-100 Index.
The company has been recognized for innovation and workplace culture by organizations such as Fast Company and Forbes, reflecting its position as a leading player at the intersection of biotechnology and cutting-edge data science. Amgen continues to advance a broad and deep pipeline of medicines while integrating artificial intelligence and other advanced technologies into its research and commercial operations.
Average Trading Volume: 2,753,661
Technical Sentiment Signal: Strong Buy
Current Market Cap: $188.8B
For an in-depth examination of AMGN stock, go to TipRanks’ Overview page.